Synthesis and In‐Vitro Activity of New 1β‐Methylcarbapenem Derivatives as Antibacterial Agents

The synthesis of a new series of 1β‐methylcarbapenems having pyrrolidine and piperidine moieties is described. Their in‐vitro antibacterial activities against both Gram‐positive and Gram‐negative bacteria were tested and the effect of substituents on the pyrrolidine ring was investigated. A particular compound III b having an oxime‐pyrrolidine moiety showed the most potent antibacterial activity.     

Design and Synthesis of Novel Pyrazino[2,1‐a]isoquinolin Derivatives with Potent Antifungal Activity

A series of novel pyrazino[2,1‐a]isoquinolin compounds were designed, synthesized, and their antifungal activities in vitro were evaluated. The results showed that all of the title compounds exhibited antifungal activities. Most of them exhibited stronger antifungal activities than the lead compounds; compound 7c is more potent than fluconazole against two of the three tested fungal strains. The studies presented here provide a new structural type for the development of novel antifungal agents.     

Synthesis,Antibacterial and Antifungal Activities of Novel 1,2,4‐Triazolium Derivatives

A series of novel 1,2,4‐triazolium derivatives was synthesized starting from commercially available 1H‐1,2,4‐triazole, 2,4‐dichlorobenzyl chloride, or 2,4‐difluorobenzyl bromide. Their antibacterial and antifungal activities were evaluated against Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, Bacillus proteus, Bacillus subtilis, Pseudomonas aeruginosa, Candida albicans ATCC 76615, and Aspergillus fumigatus. All structures of the new compounds were confirmed by NMR, IR, and MS spectra, and elemental analyses. The antimicrobial tests showed that most of synthesized triazolium derivatives exhibit significant antibacterial and antifungal activities in vitro. 1‐(2,4‐Difluorobenzyl)‐4‐dodecyl‐1H‐1,2,4‐triazol‐4‐ium bromide and 1‐(2,4‐Dichlorobenzyl)‐4‐dodecyl‐1H‐1,2,4‐ triazol‐4‐ium bromide were the most potent compounds against all tested strains with the MIC values ranging from 1.05 to 8.38 μM. They exhibited much stronger activities than the standard drugs chloramphenicol and fluconazole which are in clinical use. The results also showed that the antimicrobial activities of triazolium derivatives depend upon the type of substituent, the length of the alkyl chain, and the number of triazolium rings.     

Synthesis and Antibacterial Activity of Novel 4″‐O‐Carbamoyl Erythromycin‐A Derivatives

Novel 4″‐O‐carbamoyl erythromycin‐A derivatives were designed, synthesized, and evaluated for their in‐vitro antibacterial activities. All of the 4″‐O‐carbamoyl derivatives showed excellent activity against erythromycin‐susceptible Staphylococcus aureus ATCC25923, Streptococcus pyogenes, and Streptococcus pneumoniae ATCC49619. Most of the 4″‐O‐arylalkylcarbamoyl derivatives displayed potent activity against erythromycin‐resistant S. pneumoniae encoded by the mef gene and greatly improved activity against erythromycin‐resistant S. pneumoniae encoded by the erm gene or the erm and mef genes. In particular, the 4″‐O‐arylalkyl derivatives 4c–4e and 4g were found to possess the most potent activity against all the tested erythromycin‐susceptible strains, which were comparable to those of erythromycin, clarithromycin, or azithromycin. 4″‐O‐Arylalkyl derivatives 4e and 4g were the most effective against erythromycin‐resistant S. pneumoniae encoded by the mef gene (0.25 and 0.25 µg/mL). 4″‐O‐Arylalkyl derivatives 4a and 4b exhibited significantly improved activity against erythromycin‐resistant S. pneumoniae encoded by the erm gene. In contrast, the 4″‐O‐alkylcarbamoyl derivatives hardly showed improved activity against all the tested erythromycin‐resistant strains.     

Synthesis and preliminary pharmacological screening of novel imidazo[2,1-f]theophylline derivatives

The three different kinds of imidazo[2,1-f]theophylline derivatives were synthesized and tested for their CNS activity. A series of alkoxy-alkylamides and amino-alkylamides with basic function, derived from 8-benzyl-6,7-dihydroimidazo[2,1-f]theophylline-7-carboxylic acid showed stimulating influence on CNS as they increased the locomotor activity (compound 8 and 10) or enhanced amphetamine and apomorphine effects in mice (compounds 3, 4 and 9). Compounds 1, 5, 8-10 and 12 had anticonvulsant activity in the pentetrazole test; 12 with anellated imidazol-7-on ring (lactam structure) showed sedative properties and antiserotonin effects.     

Synthesis,Hypoglycaemic, Hypolipidemic and PPARγ Agonist Activities of 5‐(2‐Alkyl/aryl‐6‐Arylimidazo[2,1‐b][1,3,4]thiadiazol‐5‐yl)methylene‐1,3‐Thiazolidinediones

A novel series of 5‐(2‐alkyl/aryl‐6‐arylimidazo[2,1‐b][1,3,4]thiadiazol‐5‐yl)methylene‐1,3‐thiazolidinediones were synthesized as possible PPARγ agonists. The structures of these target molecules were established by spectral and analytical data. All the newly synthesized compounds were screened for their in vivo hypoglycaemic and hypolipidemic activity in male Wistar rats. Further, compounds with good activity were screened for PPARγ agonist activity. Among the screened compounds, 5‐{[2‐Cyclohexyl‐6‐(4‐methoxyphenyl)imidazo[2,1‐b] [1,3,4]thiadiazol‐5‐yl]methylene}‐1,3‐thiazolidine‐2,4‐dione (3i) exhibits promising hypoglycaemic and hypolipidemic activity via potential PPARγ agonist activity.     

Synthesis and Biological Evaluation of 2‐Mercapto‐1,3‐benzothiazole Derivatives with Potential Antimicrobial Activity

The enhancement of bacterial resistance of pathogens to currently available antibiotics constitutes a serious public health threat. So, intensive efforts are underway worldwide to develop new antimicrobial agents. To identify compounds with a potent antimicrobial profile, we designed and synthesized low molecular weight 2‐mercaptobenzothiazole derivatives 2a – 2l and 3a – 3l . Both series were screened for in‐vitro antibacterial activity against the representative panel of Gram‐positive and Gram‐negative bacteria strains. The biological screening identified compounds 2e and 2l as the most active ones showing an interesting antibacterial activity with MIC values of 3.12 μg/mL against Staphylococcus aureus and 25 μg/mL against Escherichia coli, respectively. The replacement of the S‐H by the S‐Bn moiety resulted in considerable loss of the antibacterial action of the 3a – 3l series. The antibiotic action of compounds 2e and 2l was also investigated by testing their activity against some clinical isolates with different antimicrobial resistance profile. Moreover, the involvement of the NorA efflux pump in the antibacterial activity of our molecules was evaluated. Finally, in this paper, we also describe the cytotoxic activity of the most interesting compounds by MTS assay against HeLa and MRC‐5 cell lines.     

Novel lβ‐Methylcarbapenems Having Cyclic Sulfonamide Moieties: Synthesis and Evaluation of in‐vitro Biological Activity – Part II

The synthesis of a new series of 1β‐methylcarbapenems having cyclic sulfonamide moieties is described. Their in‐vitro antibacterial activities against both Gram‐positive and Gram‐negative bacteria were tested and the effect of a substituent on the pyrrolidine ring was investigated. One particular compound IIIe having a [1,2,5]thiadiazolidin 1,1‐dioxide moiety showed the most potent antibacterial activity.     

Synthesis and Antimicrobial Activities of a Novel Series of Heterocyclic α‐Aminophosphonates

Two series of novel α‐aminophosphonates having heterocyclic moieties were synthesized in high yields. The structures of the newly synthesized compounds were confirmed by their elemental analyses, IR, ¹H NMR and MS spectral data. These compounds were screened for their antibacterial activities against Escherichia coli (NCIM2065) as a Gram‐negative bacterium, Bacillus subtilis (PC1219) and Staphylococcus aureus (ATCC25292) as Gram‐positive bacteria, and Candida albicans and Saccharomyces cerevisiae as fungi. The minimum inhibitory concentrations (MICs) of the synthesized compounds show high antibacterial and antifungal activities at low concentrations (10–1000 µg/mL). Furthermore, their lethal doses indicated that such compounds are safe for use as antimicrobial agents.     

Synthesis and Anticonvulsant Activity of Ethyl 2,2‐dimethyl‐1‐(2‐substitutedhydrazinecarboxamido) Cyclopropanecarboxylate Derivatives

In this study on the development of new anticonvulsants, fourteen ethyl 2,2‐dimethyl‐1‐(2‐substitutedhydrazinecarboxamido) cyclopropanecarboxylate derivatives were synthesized and tested for anticonvulsant activity using the maximal electroshock, subcutaneous pentylenetetrazole screens, which are the most widely employed seizure models for early identification of candidate anticonvulsants. Their neurotoxicity was determined applying the rotorod test. Two compounds 6f and 6k showed promising anticonvulsant activities in both models employed for anticonvulsant evaluation. The most active compound 6k showed the maximal electroshock‐induced seizures with ED₅₀ value of 9.2 mg/kg and TD₅₀ value of 387.5 mg/kg after intraperitoneally injection to mice, which provided compound 6k with a protective index (TD₅₀/ED₅₀) of 42.1 in the maximal electroshock test.     

Synthesis and In Vitro Antibacterial Activity of 7‐(3‐Alkoxyimino‐4‐methyl‐4‐methylaminopiperidin‐1‐yl)‐fluoroquinolone Derivatives

A series of novel 7‐(3‐alkoxyimino‐4‐methyl‐4‐methylaminopiperidin‐1‐yl)fluoroquinolone derivatives were designed, synthesized, and characterized by ¹H‐NMR, MS, and HRMS. These fluoroquinolones were evaluated for their in‐vitro antibacterial activity against representative Gram‐positive and Gram‐negative strains. Generally, all of the target compounds have considerable antibacterial activity against the tested forty strains, and exhibit exceptional potency in inhibiting the growth of methicillin‐sensitive Staphylococcus aureus (MSSA) and methicillin‐resistant S. aureus (MRSA) ATCC33591 (MICs: 0.06 to 2 μg/mL). In particular, compounds 14 , 19 , 28 , and 29 are fourfold more potent than ciprofloxacin against MSSA 08‐49. Compounds 23 , 26 , and 27 are twofold more potent than ciprofloxacin against MRSA ATCC33591 and MSSA ATCC29213. In addition, compound 14 exhibits excellent activity (MIC: 0.06 μg/mL) against Acinetobactes calcoaceticus, which is two‐ to 16‐fold more potent than the reference drugs gemifloxacin, levofloxacin, and ciprofloxacin.     

Synthesis and Antibacterial Activity of a New Series of 3‐[3‐(Substituted Phenyl)‐1‐Isonicotinoyl‐1H‐Pyrazol‐5‐yl]‐2H‐Chromen‐2‐one Derivatives

A novel series of 3‐[3‐(substituted phenyl)‐1‐isonicotinoyl‐1H‐pyrazol‐5‐yl]‐2H‐chromen‐2‐one derivatives 4a – k have been synthesized by the reaction of 3‐[2,3‐dibromo‐3‐(substituted phenyl) propanoyl]‐2H‐chromen‐2‐one 3a – k and isonicotinic acid hydrazide in the presence of triethylamine in absolute ethanol, characterized by spectral data and screened for their in‐vitro antibacterial activity against Gram‐positive and Gram‐negative bacteria. Among the series, compounds 4e , 4i , and 4k displayed an encouraging antibacterial activity profile as compared to the reference drug ampicillin against tested bacterial strains.     

Conformationally Constrained Analogs of N‐Substituted Piperazinylquinolones: Synthesis and Antibacterial Activity of N‐(2,3‐Dihydro‐4‐hydroxyimino‐4H‐1‐benzopyran‐3‐yl)‐piperazinylquinolones

A series of novel quinolone agents bearing a particular bulky and conformationally constrained bicyclic substituent (2,3‐dihydro‐4‐hydroxyimino‐4H‐1‐benzopyran‐3‐yl‐ moiety) on the piperazine ring of 7‐piperazinyl quinolones (norfloxacin, enoxacin, ciprofloxacin, and levofloxacin) were synthesized and evaluated against a panel of Gram‐positive and Gram‐negative bacteria. Among these derivatives, ciprofloxacin counterpart 9c , highly inhibited the tested Gram‐positive bacteria, superior to that of the reference drugs, and displayed antibacterial activity at non‐cytotoxic concentrations.     

Synthesis and Antimicrobial Activity of Some Novel 2‐[4‐(Substituted Piperazin‐/Piperidin‐1‐ylcarbonyl)phenyl]‐1H‐benzimidazole Derivatives

In this study, we report the synthesis and antimicrobial evaluation of several new 4‐(1H‐benzimidazol‐2‐yl)benzamides ( 11 – 30 ) and 5‐chloro‐1‐(p‐fluorobenzyl)‐2‐{4‐[(4‐methylpiperazin‐1‐yl)carbonyl]phenyl}‐1H‐benzimidazole ( 33 ). Compound 20 exhibited the best antibacterial activity with MIC value of 6.25 μg/mL against Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus (MRSA). Significant antifungal activities were obtained with the compounds 13 , 14, 18 , 19, and 33 with MIC values of 3.12 μg/mL which are close to fluconazole.